Background/Aims: Our study aimed to evaluate the effect of oral litholysis in patients with chronic calcific pancreatitis (CCP) unresponsive to or ineligible for extracorporeal shock wave lithotripsy (ESWL) and endoscopic therapy. Methods: Trimethadione, an antiepileptic agent, was administered orally at a dose of 0.6-0.9 g/day to 15 patients with this condition. Treatment outcome was evaluated by assessment of dissolution of the pancreatic stones on plain X-ray films and computed tomography scans of the upper abdomen. Plasma glucose, hemoglobin A1c, and body mass index (BMI) were also monitored throughout the therapy. Results: Litholysis was observed in 13 out of 15 patients (86.7%) and was definite in 10 and partial in 3. Six patients had pancreatitis attacks during the therapy; 5 of whom showed definite litholysis and had only 1 mild attack. Of the 11 patients with normal or impaired glucose tolerance at baseline, none developed diabetes mellitus and all showed litholysis. BMI significantly increased in patients whose pancreatic stones dissolved. There was no vital organ impairment by trimethadione. Conclusion: Oral litholysis using trimethadione may represent a noninvasive and effective complementary treatment in patients with CCP unresponsive to or ineligible for ESWL and endoscopic therapy.
Introduction
Chronic calcific pancreatitis (CCP), which was previously believed to be a terminal complication of chronic pancreatitis, is the most clear-cut form of chronic pancreatitis that remains intractable [1] . However, new therapeutic tools and techniques have been developed for the condition. Extracorporeal shock wave lithotripsy (ESWL), endoscopic therapy, and surgical therapy are effective for the elimination of pancreatic stones and can rapidly relieve the pain associated with stones that are primarily located in the main pancreatic duct (MPD) [2] [3] [4] [5] [6] [7] . How- ever, some patients are not good candidates for or do not respond to ESWL and endoscopic therapy.
Pancreatic stones, primarily comprising calcium carbonate (CaCO 3 ), are formed in the pancreatic ducts, induce chronic inflammation of the pancreas, and reduce pancreatic function to varying degrees. Trimethadione (3,5,5-trimethyl-2,4-oxazolidinedione) is an old medicine that has been used to prevent absence seizures. It is converted by metabolic demethylation to dimethadione (5,5-dimethyl-2,4-oxazolidinedione), a weak organic acid with a molecular weight of 129.14.
Dimethadione accumulates significantly in the pancreas [8] , is excreted into the pancreatic juice at high concentrations [9] [10] [11] [12] , and dissolves CaCO 3 [13] [14] [15] [16] . Oral litholysis using a dimethadione precursor, trimethadione, was previously developed and shown to have efficacy for CCP as a noninvasive oral litholytic therapy (OLT) [17] [18] [19] .
The present study is an extension of our previous studies on the chemical dissolution of pancreatic stones and describes the effect of OLT in patients who did not respond to or were ineligible for ESWL and endoscopic therapy.
Methods

Participants
The present study was approved by the ethics review board of Aichi Medical University and was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all study participants. The study included 15 patients (10 males and 5 females), with an average age of 50.5 years. All patients who were referred to our department from another medical facility were enrolled in this study. The patients' clinical background and history of treatment at baseline are listed in Table 1 . Alcohol abuse was recognized as a causative factor if intake of ethanol was > 80 g/day over the course of 10 years. Two-thirds of the patients had alcoholrelated chronic pancreatitis, and the remaining patients had idiopathic pancreatitis. Plain X-ray film and/or computed tomography (CT) scans of the upper abdomen showed that the distribution of the stones was diffuse in 80%, and the size of the stones [17] was small and mixed (large and small) in 94%.
Glucose tolerance was assessed according to the Evidencebased Practice Guideline for the Treatment for Diabetes in Japan, proposed by The Japan Diabetes Society [20] . The results were classified into 3 categories: normal glucose tolerance, borderline or impaired glucose tolerance (IGT), and diabetes mellitus. Normal glucose tolerance was observed in 46.7%, IGT in 26.7%, and diabetes mellitus in 26.7% (Table 1 ). In the present study, patients with normal glucose tolerance and IGT were assigned to the non-diabetes group. All patients, except one, had a history of hospitalization for pancreatitis attack prior to undergoing OLT. In the remaining patient who had no pain attacks, pancreatic stones were incidentally found during careful examination for hyperthyroidism.
ESWL and endoscopic therapy were performed in 9 and 11 patients, respectively, and both therapies were carried out in 8 patients in another medical facility prior to starting OLT. Four or more sessions of ESWL (8 sessions maximum) were performed using piezoelectric, spark gap, or electromagnetic induction system, and endoscopic therapy was performed by experienced endoscopists. These therapies, however, failed to sufficiently eliminate the pancreatic stones (Table 1) . In all 9 patients who underwent ESWL, the primary factors for unsuccessful stone elimination included stenosis of the MPD in 6 patients (66.7%), sharp curvature of the MPD in 2 patients (22.2%), and incarceration of the stones near the major papilla in 1 patient (11.1%). The remaining 6 patients were deemed ineligible for ESWL due to post-longitudinal pancreaticojejunostomy (LPJ) status (n = 3), presence of large or multiple cysts in the pancreas (n = 2), and compact incarceration of the stones (n = 1). In the 11 patients who underwent endoscopic therapy, the primary factors for unsuccessful treatment outcome included stenosis of the MPD in 6 patients (54.5%), sharp curvature of the MPD or incarceration of the stones in 4 patients (36.4%), and multiple cysts in the pancreas in 1 patient (9.1%). The remaining 4 patients were deemed ineligible for endoscopic therapy, primarily because of post-LPJ status (n = 3) and irregular stenosis throughout the MPD (n = 1). Stent placement and endoscopic sphincterotomy were also performed in 4 and 2 patients, respectively.
Trimethadione Administration
Eligibility for OLT was based on previously described criteria [17] , with few modifications. Specifically, patients were considered eligible for OLT if they: (1) desired to undergo OLT; (2) were deemed capable of personal care or stated they were to the attending physician; (3) did not have a serious disorder of the liver, kidneys, blood, eyes, or skin; (4) did not have malignancy or findings that were suspicious for malignancy; (5) were not pregnant and did not intend to become pregnant during treatment (female patients); (6) did not have glucose tolerance abnormalities or had sufficient control of blood glucose levels if such abnormalities existed; and (7) were not hypersensitive to trimethadione.
Trimethadione was administered at a dose of 0.6 g/day, divided into 3 daily portions for the first 1-2 months. If no adverse reactions occurred, the dose was increased to 0.9 g/day. Patients who missed the mid-day dose were allowed to take 0.6 g/day. Patients were also administered either their usual dose or double their usual dose of a pancreatic enzyme preparation.
Measurements
Pancreatic stones were generally evaluated by at least 2 specialists every 3-4 months by plain X-ray film of the upper abdomen and every 4-6 months using abdominal CT scan. The extent of litholysis during treatment was defined relative to the size and number of pancreatic stones at baseline. Litholysis was considered definite if the number or size of the pancreatic stones decreased by ≥50%, partial if the number or size of the pancreatic stones decreased by <50%, or none, when litholysis had not occurred [17] . Changes in the pancreatic and biliary ducts were evaluated using magnetic resonance cholangiopancreatography or endoscopic retrograde cholangiopancreatography (ERCP).
Changes in endocrine function were principally evaluated based on plasma glucose (PG) and hemoglobin A1c (HbA1c) levels. In addition, nutritional status was assessed using body mass index (BMI). Routine blood examinations were performed every 3-4 months to monitor vital organ impairment due to trimethadione. Ophthalmoscopy was performed once or twice per year. The mean follow-up period for the litholytic therapy was 78 months (95% CI 53.7-102.3).
Significant differences in HbA1c level and BMI from baseline and during OLT were tested using Wilcoxon matched-pairs signed-ranks test (Python CGI, Python Software Foundation, Wilmington, DE, USA). A value of p < 0.05 was regarded as statistically significant.
Here, 2 representative cases from this series are presented.
(1) Patient 1 was a 31-year-old female with alcohol-related pancreatitis. ERCP revealed stenosis of the MPD in the head of the pancreas, dilatation of the distal pancreatic ducts (Fig. 1a) , and multiple floating stones in the MPD (Fig. 1b) . ESWL and endoscopic stone removal therapy were performed 4 sessions and 4 times, respectively, followed by pancreatic duct stent placement. However, the pancreatic stones continued to recur, and the patient was referred to our department. ERCP was performed at 35 months after starting OLT and showed significant improvement of the MPD stenosis in the head of the pancreas (Fig. 2, arrow) as well as markedly fewer stones.
At baseline, plain abdominal CT showed diffuse stones of various sizes in the dilated MPD and its branches, as well as atrophy of the pancreatic parenchyma (Fig. 3a) . Plain abdominal CT performed at 37 months after starting OLT showed a significant decrease in the number and size of the pancreatic stones (Fig. 3b) .
Glucose tolerance was normal both at baseline and during treatment (random PG level: 90-159 mg/dL; HbA1c: 5.1-6.1%). The patient's BMI was 16.4 kg/m 2 prior to starting OLT and was maintained between 18 and 19 kg/m 2 during OLT. There was no macroscopic steatorrhea. Pancreatic duct stents were replaced every 6 months at the referring hospital, and OLT was continued with the patient's consent. (2) Patient 2 was a 32-year-old female with non-alcohol-related pancreatitis and multiple pancreatic stones. She was referred to our department for OLT; however, only minimal dissolution of the stones was achieved. Plain abdominal CT at 61 months after starting OLT indicated incarceration of relatively large stones in the MPD in the head of the pancreas and dilated distal pancreatic ducts (Fig. 4) . The pancreatic parenchyma had atrophied in the body and tail but was well-preserved in the head (Fig. 4) .
OLT was discontinued, and ESWL was performed 4 sessions and endoscopic treatments, including papillotomy were carried out twice at another facility; however, stone breakdown and elimination were not achieved. OLT was restarted, and 10 months later, the patient experienced a mild pancreatitis attack [21] . Abdominal CT showed that the stones in the MPD in the head of the pancreas had elongated, thinned out, and flattened, suggesting they were in the process of being passed into the duodenum (Fig. 5a) . Two months later, abdominal CT did not show any stones, indicating that these had been passed (Fig. 5b) . At the time of the pancreatitis attack, magnetic resonance cholangiopancreatography showed a signal defect (Fig. 6a, arrow) and dilatation of the distal pancreatic duct, which both resolved after 2 months (Fig. 6b) . The small cyst in the body of the pancreas did not change significantly.
Glucose tolerance was normal at baseline and remained normal during treatment (random PG level: 77-100 mg/dL; HbA1c: 5.0-5.9%), and BMI was 20.7-21.0 kg/m 2 . Minute stones remained in the head of the pancreas, but OLT was discontinued with the patient's agreement. No marked changes were noted at the last visit (19 months).
Results
Dissolution of the Pancreatic Stones
The outcomes of litholysis by OLT are shown in Table  2 . Litholysis was observed in a total of 13 patients (86.7%), and was definite in 10 and partial in 3. In these patients, the etiology was alcohol-related in 9 (69.2%) and idiopathic in 4 (30.8%). The 2 patients who did not achieve litholysis had family and social problems, as well as poor adherence to OLT and poor personal care, including frequent snacking and substantial alcohol consumption. Of the 3 patients who had previously undergone LPJ, 2 showed definite litholysis and 1 showed partial litholysis.
Pancreatic Endocrine Function and BMI
All 11 patients in the non-diabetes group achieved stone dissolution for a mean duration of 44.1 months (range 12-93 months) of OLT ( Table 2 ). In these patients, PG levels remained normal or borderline during OLT, and the highest HbA1c value did not significantly differ from that immediately prior to treatment (6.0%, 95% CI 5.7-6.3 vs. 5.8%, 95% CI 5.3-6.3; p > 0.05). Two of four patients with IGT continued to use oral hypoglycemic agents, including voglibose and gliclazide at the same or almost the same doses as those taken prior to treatment. Overall, there were no newly diagnosed cases of diabetes mellitus.
One of the 4 patients with diabetes mellitus achieved partial litholysis during OLT and maintained good control of her diabetes without changing the dose or type of insulin ( Table 2 ). The other patient with diabetes mellitus showed definite litholysis and had relatively good control of his diabetes during OLT; however, he had recurrence of pancreatic stones after deciding to discontinue OLT and eventually required insulin administration ( Table 2) . The remaining 2 patients with diabetes mellitus had various problems, as described above, as well as poor diabetes control.
In the non-diabetes group, the highest mean BMI was significantly higher during OLT compared with baseline 
Pancreatitis Attack
Six patients had pancreatitis attacks during OLT; 5 of these showed definite litholysis and had only 1 mild attack [21] . The remaining patient, with poor treatment adherence and no dissolution of stones, experienced 2 pancreatitis attacks after excessive alcohol and food consumption. 
Adverse Reactions to Trimethadione
Mild photophobia without fundus abnormalities was observed in 9 patients (60.0%) and was effectively managed by wearing sunglasses when outdoors. No abnormality was found in their eyegrounds. No laboratory findings suggestive of trimethadione toxicity were found in the liver, kidneys, blood, skin, or mucosa.
Completion and Continuation
Five patients who achieved definite litholysis wanted to continue OLT for further dissolution of the residual stones. The other 10 patients discontinued OLT; 8 patients agreed to discontinue OLT after a mean period of 57.6 months and 2 patients decided to discontinue OLT after a mean treatment period of 45 months. Of these patients who discontinued OLT, 4 showed definite litholysis, 4 showed partial litholysis, and 2 showed no litholysis. The interim progress of 2 patients, who were different from those presented in the previous section, has already been described elsewhere [18, 19] .
Discussion
Pancreatic stones restrict or prevent the outflow of pancreatic fluid and increase the pancreatic intraductal pressure, causing pain and worsening pancreatic function to varying degrees [22] . Experimental models have demonstrated that decreasing the pancreatic intraductal pressure improves edema, fibrosis, and pancreatic microvascular blood flow, and restores the residual function of the pancreatic endocrine cells [23] [24] [25] .
The presence of pancreatic stones does not necessarily indicate burnout of the pancreas [1] . In recent years, new treatment modalities for pancreatic stones have been developed. ESWL, endoscopic therapy, and LPJ are effective for stone removal from large pancreatic ducts, especially the MPD, and for rapid, long-term pain relief [3, 6, 26, 27] . However, these treatment modalities may fail for varb a Fig. 3 . Plain computed tomography images in Patient 1. a There is diffuse distribution of several stones, marked dilatation of the MPD, and parenchymal atrophy immediately before OLT initiation. b At 37 months after OLT initiation, the number and sizes of the stones are markedly decreased. ious reasons and cannot always be applied. A Japanese multicenter study showed that the rate of stone elimination achieved by concomitant ESWL and endoscopic therapy was approximately 70%; however, stone recurrence rate after treatment was 22% and was particularly high in patients with stenosis of the MPD [6] . The recent report described that surgery should be performed on patients in whom ESWL and endoscopic therapy failed [7] . The effect of these modalities on long-term pancreatic function remains unclear.
Unlike stones in the MPD, stones in the peripheral pancreatic ducts do not necessarily cause severe pancreatitis attacks; however, they are believed to persistently increase the pancreatic intraductal pressure, causing a gradual decline in pancreatic function. However, these stones are not necessarily good targets for ESWL or endoscopic therapy. Preservation of the pancreatic parenchyma and function can be achieved by dissolving immature stones with low CaCO 3 content as well as mall stones that have already matured in the peripheral and the larger ducts.
In the present study, pancreatic stones were successfully dissolved in 87% of patients, regardless of the etiology of chronic pancreatitis. To date, we have not encoun- tered any cases of spontaneous dissolution of pancreatic stones. Furthermore, considering the findings of previous studies involving the in vitro dissolution of stones [13, 14] , as well as the dog experimental model of litholysis [16] , it is evident that pancreatic stone dissolution does not occur spontaneously, but occurs as a result of trimethadione administration.
Since stone dissolution is gradual, trimethadione administration was conducted over an extended period; therefore, it is likely that patient adherence will have affected treatment outcome. In agreement, litholysis was only achieved in patients with good adherence. In the present and previous studies [17] , there was no case in which litholytic therapy had to be discontinued because of adverse effects of trimethadione. The concomitant mechanisms of action of multiple procedures should also be considered in terms of treatment success. ESWL aims to break or crack stones, which increases the contact surface between the stones and the pancreatic juice containing dimethadione, and ultimately promotes stone dissolution [14] . Endoscopic therapy aims to eliminate as many stones as possible from the ducts and ultimately improves the outflow of pancreatic juice. On the other hand, dimethadione shrinks and disintegrates stones, leading to smooth clearance of stones from the ducts [18, 19] . These overlapping mechanisms of action appear to have played roles in the representative cases of patients 1 and 2 who underwent ESWL and endoscopic therapy prior to or during OLT, implying the usefulness of litholytic therapy combined with ESWL and endoscopic therapy. In patients who underwent LPJ prior to starting OLT, it is likely that even if the anastomotic opening was narrower, dimethadione-induced shrinkage or disintegration of the stones further facilitated their elimination. Indeed, dissolution of pancreatic stones was observed in all 3 patients with previous LPJ.
Glucose intolerance is a major complication of CCP and reduces quality of life to varying degrees. The present study showed well-preserved glucose tolerance and increased BMI in patients whose pancreatic stones were dissolved, highly suggestive of a favorable effect of OLT on pancreatic endocrine function and nutritional status. Based on the results obtained using experimental models of obstructive pancreatitis [23, 24] , dissolution of pancreatic stones may prevent elevated pancreatic intraductal pressure, avoid the progressive destruction of the islets of Langerhans, and preserve pancreatic endocrine function. Recently, Ashizawa et al. [19] provided more precise evidence for the therapeutic effect of OLT on pancreatic endocrine function by calculating the total calcified stone volume using computer analysis of follow-up CT images and a follow-up 75-g oral glucose tolerance test.
In the present study, 40% of patients had mild pancreatitis attacks during OLT, and almost all showed definite litholysis. As shown in the case of patient 2, stones that shrank or were disintegrated into pieces by the action of dimethadione were likely to have been temporarily impacted into the major papilla, causing an increase in the intraductal pressure and inducing a pancreatitis attack. OLT is less effective for the rapid relief of pain compared with ESWL and endoscopic therapy, but may lead to long-term pain relief by reducing the intraductal pressure over an extended period [17] .
To the best of our knowledge, there are no simple, highly sensitive, sufficiently specific, and reproducible tests to evaluate the exocrine pancreatic function; therefore, pancreatic exocrine function was not assessed in the present study. Patients received their usual or double their usual dose of pancreatic enzyme preparation during the study. There were no reports of macroscopic steatorrhea or decrease in BMI in patients whose pancreatic stones dissolved. The effects of OLT on pancreatic exocrine function, as well as the decision to complete or continue the treatment, remain to be elucidated.
In conclusion, the findings from the present study, while small in sample size, suggest that oral litholysis using trimethadione combined with good personal care of the patient, represent a noninvasive and complementary treatment with favorable outcomes in patients unresponsive to or ineligible for ESWL and endoscopic therapy. In the near future, new treatments for stones dissolution may be developed, and chemical litholysis may be combined with stones disintegration by ESWL and endoscopic therapy to achieve a more effective treatment for CCP.
